<DOC>
	<DOCNO>NCT00563940</DOCNO>
	<brief_summary>Diabetic macular edema common complication ocular diabetes mellitus cause blindness . Hypoxygenation retina stimulates tissue mediator , especially different subtypes vascular endothelial growth factor ( VEGF ) . VEGF responsible proliferation , extension increase permeability vessel . The aim study examine short-term effect intravitreal bevacizumab ( Avastin® 1.25 mg 0.05 ml ) triamcinolone visual acuity central retinal thickness patient clinically significant diabetic macular edema ( CSME ) .</brief_summary>
	<brief_title>Short-term Effects Intravitreal Bevacizumab Triamcinolone Patients With Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>clinical significant macular edema retinal thickness &lt; 250 µm</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>diabetic macular edema</keyword>
	<keyword>OCT</keyword>
</DOC>